Theraclion

Theraclion is a French company, formed in 2004 as a spin-off from Edap-Technomed, and is a pioneer in the therapeutic use of ultrasound. Theraclion develops, manufactures and markets the Echopulse® medical device for the non-invasive, outpatient treatment of breast fibroadenomas and benign thyroid nodules. Theraclion has obtained ISO 13485 certification and CE marking for two pathologies. Theraclion is Based in Malakoff, near Paris. 53% of its 30 staff are dedicated to R&D and clinical trials. Theraclion is currently the only company in the world offering a completely non-invasive treatment for breast fibroadenomas and benign thyroid nodules. This solution is a genuine alternative to surgery and to minimally-invasive techniques. Theraclion has been focusing on research and development for the past 10 years, and is now extending its activities by investing in various scientific and medical programmes. To achieve this, Theraclion has secured the support of a long-term investor and majority shareholder, Truffle Capital. As a mark of Theraclion’s success, Bpifrance (formerly OSEO) has granted financial support to Theraclion for its involvement in several different projects such as the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy. Theraclion also won the Frost & Sullivan Award for innovation in 2009.
Type
Public
HQ
Malakoff, FR
Founded
2004
Size (employees)
22 (est)
Theraclion was founded in 2004 and is headquartered in Malakoff, FR

Theraclion Office Locations

Theraclion has an office in Malakoff
Malakoff, FR (HQ)
102 Rue Etienne Dolet

Theraclion Data and Metrics

Theraclion Financial Metrics

Numbers are in €, EUR

Market capitalization (22-Mar-2017)

23.5 m

Closing share price (22-Mar-2017)

4.9
Theraclion's current market capitalization is €23.5 m.

Theraclion Market Value History

Theraclion Online and Social Media Presence

Theraclion News and Updates

Theraclion Company Life and Culture

You may also be interested in